




AstraZeneca GI Franchise
Dr Hans Glise
Vice President, Head of GI Area

Leadership in GI

“A growing portfolio
in a growing segment”




Proton Pump Inhibitors vs global pharmaceutical market Average annual growth MAT Q2 1995–MAT Q2 2000



Source: IMS Health 34 countries

AstraZeneca 

AstraZeneca in GI



Gastroesophageal Reflux Disease (GERD)

Dyspepsia


Peptic Ulcer Disease (PUD)

Irritable Bowel Syndrome (IBS)

Inflammatory Bowel Disease (IBD)


AstraZeneca 

Prevalence of GI disorders



AstraZeneca 

Gastroesophageal Reflux Disease (GERD)



Mechanisms

Pathophysiology

Symptomatology

- Mild-to-severe symptoms


Consequences

- Poor quality of life
- Decreased productivity
- Increased risk for esophageal cancer


AstraZeneca 

Indirect costs for GERD

% Reduced productivity



Weekly indirect cost untreated moderate GERD US\$




Wahlqvist P, et al. Medical Decision Making 1999;19:532.



Direct costs for GERD


US\$ per patient



Levin TR, et al. Am J Med 1997;107:520-28.



Cost of GERD



AstraZeneca 

GERD treatment – AstraZeneca

1. Acid inhibition

- Losec® / Prilosec®
- Nexium®
- Reversible acid pump inhibitor drug

AstraZeneca 

GERD treatment – AstraZeneca

1. Acid inhibition


- Losec® / Prilosec®
- Nexium®
- Reversible acid pump inhibitor drug

2. Reflux inhibition

- GABA_B agonist



Reversible acid pump inhibitor Day 1 acid inhibition in healthy volunteers



Data on File



Reversible acid pump inhibitor

Median intragastric pH in healthy volunteers and DU patients – first dose



Data on File

Adapted from Cederberg et al 1992 (omeprazole)

AstraZeneca 


Reversible acid pump inhibitor

Effect in man

- Rapid onset
- Full effect after first dose
- Dose-dependent effect
- Same effect dose after dose
- Flexible


AstraZeneca 

Reflux inhibition



AstraZeneca 

Reflux inhibition




* Transient lower esophageal sphincter relaxations
Lidums et al., 2000; Holloway et al., 2000

AstraZeneca 

Reflux inhibition


GABA_B agonist (Baclofen 40 mg – antispastic drug) significantly reduces the rate of reflux episodes in healthy volunteers and GERD patients




Lidums et al., 2000; Holloway et al., 2000



Site of action of Baclofen and AZ reflux inhibitor



Reflux inhibitor dose response



AstraZeneca 

Inflammatory Bowel Disease (IBD)

Entocort®

- US filing soon

Rofleponide

- Potent effect, targeted to disease area
- 99% first pass liver metabolism
- Minimal systemic exposure of corticosteroid

AstraZeneca 

H. pylori

↻ Medical background

- gastric inflammation
- peptic ulcer
- gastric cancer

AstraZeneca 

H. pylori

↻ *H. pylori*-specific monotherapy

- discovery phase

↻ Immunotherapy

- discovery phase


AstraZeneca 

Summary – GI emerging portfolio

	Phase
🔍 Strong pipeline for the treatment of reflux disease	Discovery and in man
🔍 Further improvement of locally acting corticosteroids in IBD	In man
🔍 New principles of treatment for <i>H. pylori</i> infection	Discovery
🔍 New principles of treating visceral hypersensitivity related to IBS and dyspepsia	Discovery

AstraZeneca 

AstraZeneca in GI



Gastroesophageal Reflux Disease (GERD)

Dyspepsia


Peptic Ulcer Disease (PUD)

Irritable Bowel Syndrome (IBS)

Inflammatory Bowel Disease (IBD)

AstraZeneca 

The GI pipeline



AstraZeneca 